Overview

Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma

Status:
Recruiting

Trial end date:
2024-03-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to determine the safety and tolerability of GS-0189 (formerly FSI-189) as monotherapy and in combination with rituximab in participants with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).

Phase:

Phase 1

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Rituximab